Shifting paradigms in the management of pediatric differentiated thyroid cancer from static to dynamic risk stratification: a step forward toward precision medicine Dynamic risk stratification and pediatric thyroid cancer

被引:2
|
作者
Ajdari, Sadegh Ebrahlm [1 ]
Shafiei, Babak [1 ]
Motazedian, Motahareh [2 ]
Qutbi, Mohsen [1 ]
Naeilzadeh, Parldokht [3 ]
Asli, Isa Neshandar [1 ]
Javadi, Hamid [4 ]
Assadi, Majid [5 ]
机构
[1] Shahid Beheshti Univ Med Sci, Taleghani Hosp, Dept Nucl Med, Tehran, Iran
[2] Shiraz Cent Hosp, Dept Nucl Med, Shiraz, Iran
[3] Urmia Univ Med Sci, Imam Khomeini Hosp, Dept Otorhinolaryngol, Orumiyeh, Iran
[4] Golestan Univ Med Sci GUOMS, GRCGH, Gorgan, Golestan, Iran
[5] Bushehr Univ Med Sci, Persian Gulf Nucl Med Res Ctr, Bushehr 3631, Iran
来源
NUKLEARMEDIZIN-NUCLEAR MEDICINE | 2019年 / 58卷 / 03期
关键词
Pediatric differentiated thyroid cancer; dynamic risk stratification (DRS); American Thyroid Association (ATA) guideline; European Thyroid Association (ETA) guideline; INITIAL THERAPY; CARCINOMA; CHILDREN; RECURRENCE; ABLATION; GUIDELINES; NODULES;
D O I
10.1055/a-0895-4997
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Introduction This study aimed to assess the usefulness of a risk-adopted management system known as dynamic risk stratification (DRS) in comparison with the American (ATA) and European Thyroid Associations' (ETA) risk classifications in the management of pediatric patients with differentiated thyroid cancer (DTC). Materials and Methods The current study included 50 pediatric patients with DTC who were treated with total or near total thyroidectomy and radioiodine ablation whose risk assessment was initially defined according to the ATA and ETA guidelines. During the two years after initial treatment, patients were reclassified according to their DRS. Results The study showed that the ability of the DRS system to predict the final outcome was superior to that of the ATA and ETA guidelines. The observed variance in predicting final outcome was 2.3 % for ETA, 14.8 % for ATA, and 83.4 % for DRS. In intermediate/high-risk patients, according to the ATA/ETA guidelines, an excellent response to initial therapy resulted in a noteworthy reduction (about 40 %) for detection of structural disease at the time of final follow-up. The risk of structural disease at the time of final follow-up was significantly higher in the structural incomplete response group (HR = 23.34, P = 0.00) and biochemical incomplete response group (HR = 13.83, P = 0.03) than in the excellent response group. Conclusion The data documented the significance of re-stratifying pediatric patients with DTC on the basis of the findings obtained at the time of or after their initial therapy (total thyroidectomy and radioiodine ablation), predominantly in the intermediate/high-risk patients. In addition, DRS helped to better modulate the later follow-up, excluding a large number of intermediate/high risk patients from needless intensive workups, allowing personalization of follow-up management.
引用
收藏
页码:249 / 257
页数:9
相关论文
共 50 条
  • [1] Shifting paradigms in the management of pediatric differentiated thyroid cancer from static to dynamic risk stratification: a step forward toward precision medicine
    Ajdari, S. Ebrahim
    Shafiei, B.
    Motazedian, M.
    Qutbi, M.
    Esmaeilzadeh, P.
    Asli, I. Neshandar
    Javadi, H.
    Assadi, M.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S130 - S131
  • [2] Validation of dynamic risk stratification in pediatric differentiated thyroid cancer
    Sohn, Seo Young
    Kim, Young Nam
    Kim, Hye In
    Kim, Tae Hyuk
    Kim, Sun Wook
    Chung, Jae Hoon
    [J]. ENDOCRINE, 2017, 58 (01) : 167 - 175
  • [3] Validation of dynamic risk stratification in pediatric differentiated thyroid cancer
    Seo Young Sohn
    Young Nam Kim
    Hye In Kim
    Tae Hyuk Kim
    Sun Wook Kim
    Jae Hoon Chung
    [J]. Endocrine, 2017, 58 : 167 - 175
  • [4] Initial and Dynamic Risk Stratification of Pediatric Patients With Differentiated Thyroid Cancer
    Sung, Tae Yon
    Jeon, Min Ji
    Lee, Yi Ho
    Lee, Yu-mi
    Kwon, Hyemi
    Yoon, Jong Ho
    Chung, Ki-Wook
    Kim, Won Gu
    Song, Dong Eun
    Hong, Suck Joon
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2017, 102 (03): : 793 - 800
  • [5] Usefulness of dynamic risk stratification in pediatric patients with differentiated thyroid carcinoma
    Kim, Kwangsoon
    Kim, Won Woong
    Choi, Jung Bum
    Kim, Min Jhi
    Lee, Cho Rok
    Lee, Jandee
    Kang, Sang-Wook
    Nam, Kee-Hyun
    Chung, Woong Youn
    Jeong, Jong Ju
    [J]. ANNALS OF SURGICAL TREATMENT AND RESEARCH, 2018, 95 (04) : 222 - 229
  • [6] Dynamic risk stratification for predicting the recurrence in differentiated thyroid cancer
    Ozkan, Elgin
    Soydal, Cigdem
    Nak, Demet
    Kucuk, Nuriye O.
    Kir, Kemal M.
    [J]. NUCLEAR MEDICINE COMMUNICATIONS, 2017, 38 (12) : 1055 - 1059
  • [7] Applicability of Adults 2015 American Thyroid Association Differentiated Thyroid Cancer Guidelines for Postoperative Risk Stratification and Postradioiodine Treatment Dynamic Risk Stratification in Pediatric Population
    Singh, Shashank Shekhar
    Mittal, Bhagwant Rai
    Sood, Ashwani
    Bhattacharya, Anish
    Kumar, Ganesh
    Shekhawat, Amit Singh
    Singh, Harpreet
    [J]. WORLD JOURNAL OF NUCLEAR MEDICINE, 2022, 21 (02) : 127 - 136
  • [8] Dynamic Risk Stratification for Predicting Treatment Response in Differentiated Thyroid Cancer
    Giannoula, Evanthia
    Melidis, Christos
    Papadopoulos, Nikitas
    Bamidis, Panagiotis
    Raftopoulos, Vasilios
    Iakovou, Ioannis
    [J]. JOURNAL OF CLINICAL MEDICINE, 2020, 9 (09) : 1 - 13
  • [9] Delayed risk stratification in differentiated thyroid cancer
    Linda Koch
    [J]. Nature Reviews Endocrinology, 2011, 7 (10) : 560 - 560
  • [10] Dynamic Risk Stratification for Predicting Long-term Outcomes in Pediatric Differentiated Thyroid Cancers
    Majeed, Althaf K.
    Satapathy, Swayamjeet
    Ballal, Sanjana
    Bal, Chandrasekhar
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 108 (06): : E208 - E215